Stocks
Fate Therapeutics (FATE) EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -96.4 | -125.7 | -215.7 | -308.4 | -159.3 | -198.8 | ||
| Changes by years, y/y, % | +49% | +30% | +72% | +43% | -48% | +19.7% | |||
Fate Therapeutics. EBITDA US GAAP, bln rub
Fate Therapeutics. EBITDA US GAAP, changes, %
Fate Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Fate Therapeutics (FATE) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| EBITDA, bln rub | ? | -24.4 | -58.1 | -51.3 | -43.2 | -46.2 | -198.8 | |
| Changes by years, y/y, % | -66% | -28% | -38% | -33% | +90% | |||
| Changes by quarters, q/q, % | -62% | +138% | -12% | -16% | +7% | |||
